Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 23 papers were listed this time. Here's a few in our areas of research interest:
Cammà C, Petta S, Cabibbo G, et al. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. J Hepatol. 2013 May 23. [Epub ahead of print] PubMed PMID: 23707373.
Chan K, Lai MN, Groessl EJ, et al. Cost-Effectiveness Analysis of Direct-Acting Antiviral Therapy for Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Infection in the Veterans Health Administration. Clin Gastroenterol Hepatol. 2013 May 22 [Epub ahead of print] PubMed PMID: 23707354.
Bartsch SM, Umscheid CA, Fishman N, et al. Is Fidaxomicin worth the cost? An economic analysis. Clin Infect Dis. 2013 May 23. [Epub ahead of print] PubMed PMID: 23704121.
Holt S, Bertelli G, Humphreys I, et al. A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK. Br J Cancer. 2013 May 21. [Epub ahead of print] PubMed PMID: 23695023.